Traws Pharma, Inc. 8-K

What Happened
Traws Pharma, Inc. (TRAW) filed an 8-K on July 10, 2026 to report an update to its previously announced "at-the-market" (ATM) offering program. The Company entered the ATM Agreement with Citizens JMP Securities, LLC on March 10, 2025, under which it may sell shares of its common stock from time to time. Under the new prospectus supplement (filed July 10, 2026) to the Form S-3 shelf (Registration No. 333-297195, declared effective July 9, 2026), the Company may offer and sell up to $5,575,709 of common stock through Citizens as its sales agent/principal—this amount reflects the Company’s current “baby shelf” limitation.

Key Details

• ATM Agreement originally entered March 10, 2025 with Citizens JMP Securities, LLC as sales agent and/or principal.
• Shelf registration: Form S-3 (Reg. No. 333-297195) filed July 1, 2026 and declared effective July 9, 2026.
• Prospectus Supplement dated July 10, 2026 allows offers/sales of up to $5,575,709 (the “baby shelf” cap under Form S-3 General Instruction I.B.6).
• A legal opinion from Snell & Wilmer L.L.P. related to the Shares was filed as an exhibit to the 8-K.

Why It Matters
This filing clarifies how much common stock Traws Pharma can sell into the market under its ATM program now that its S-3 shelf is effective. For investors, the $5.58 million baby-shelf cap is the immediate usable amount the company can raise via ATM sales through Citizens; the broader $50 million capacity in the ATM Agreement remains subject to shelf limitations. Sales under an ATM can dilute existing shareholders if shares are issued, and they provide the company with a flexible way to raise capital over time.